Rivera Fernando, Eugenia Vega-Villegas María, López Carlos, Francisca López-Brea María, Rubio Antonio, Del Valle Adolfo, García-Reija Fe, García-Montesinos Belen, Rodríguez-Iglesias Julio, Hinojo Carmen, Márquez Raul, Angel Alonso-Bermejo Miguel, Salcedo Matilde, Blanco Yolanda, Vega Noelia, López-Tarruella Sara, Sanz-Ortiz Jaime
Department of Medical Oncology, University Hospital Marqués de Valdecilla, Santander, Spain.
Acta Oncol. 2008;47(8):1584-9. doi: 10.1080/02841860802089793.
Standard treatment of patients with T4b squamous cell head and neck cancer (T4b-SCHNC) is concomitant chemo-radiotherapy (CT-RT). Recent Phase III trials with Taxane containing induction chemotherapy (IC) suggest that IC could also play a role in this setting. The value of resecting the residual mass after IC and before RT is not yet clear in this context.
We present the results of a retrospective analysis.
Between 1984 and 2001, 113 patients (patients) with T4b-SCHNC were treated at our institution with IC. Four patients dead during IC and 57 patients achieved a complete or a >90% partial response at primary and proceeded to definitive RT (or concomitant CT/RT). Surgical resection was reconsidered after IC and before RT in the other 52 patients. Surgery was performed in 13 of them: in 7 patients resection was R1, all of them had loco-regional progression (2 also developed systemic metastases) and median OS after surgery was 21 months, with no patient alive at 48 months. In the other 6 patients a R0 resection was performed: 3 of these patients had loco-regional relapses (1 also developed systemic metastases) and the other 3 patients remain alive and disease free 56, 62 and 72 months after surgery. Considering the 52 patients that achieved less than a 90% partial response at primary with IC, overall survival was equivalent when no Resection or an R1 resection was performed after IC (5 year OS 8 vs. 0%, lrk, p=0.74), but a statistically significant improvement in OS was observed when an R0 resection was obtained (5 years OS 50%, lrk, p=0.02).
R0 resections after IC and before RT could indicate an improvement in OS in patients with T4b-SCHNC that obtain less than a 90% PR at primary after IC. We consider that this approach deserves further research in prospective clinical trials.
T4b期头颈部鳞状细胞癌(T4b-SCHNC)患者的标准治疗是同步放化疗(CT-RT)。近期含紫杉烷诱导化疗(IC)的III期试验表明,IC在此种情况下也可能发挥作用。在此背景下,IC后、RT前切除残余肿块的价值尚不清楚。
我们展示了一项回顾性分析的结果。
1984年至2001年期间,我院对113例T4b-SCHNC患者进行了IC治疗。4例患者在IC期间死亡,57例患者在原发灶达到完全缓解或>90%部分缓解,并继续进行确定性RT(或同步CT/RT)。另外52例患者在IC后、RT前重新考虑手术切除。其中13例患者接受了手术:7例患者切除为R1,所有患者均有局部区域进展(2例还发生了远处转移),术后中位总生存期为21个月,48个月时无患者存活。另外6例患者进行了R0切除:其中3例患者发生局部区域复发(1例还发生了远处转移),另外3例患者术后56、62和72个月仍存活且无疾病。考虑到52例在原发灶经IC后部分缓解率低于90%的患者,IC后未进行切除或进行R1切除时总生存期相当(5年总生存率分别为8%和0%,对数秩检验,p = 0.74),但当获得R0切除时,总生存期有统计学意义的改善(5年总生存率50%,对数秩检验,p = 0.02)。
IC后、RT前进行R0切除可能表明,IC后原发灶部分缓解率低于90%的T4b-SCHNC患者的总生存期有所改善。我们认为这种方法值得在前瞻性临床试验中进一步研究。